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Abstract
Background: Cancer-related fatigue (CRF) is the most taxing symptom for many breast cancer patients during and
after therapy. In patients with metastatic disease, the prevalence of CRF exceeds 75%. Currently, there is no gold
standard for the treatment of CRF. Physical activity can reduce CRF and is recommended during and after cancer
treatment, but may be too burdensome for patients with metastatic breast cancer. The aim of this study is to assess
the effect on fatigue of eurythmy therapy (ERYT) compared to slow movement fitness (CoordiFit) in metastatic
breast cancer patients.
Methods: The ERYT/CoordiFit study is a randomized controlled, open-label, two-arm, multi-center Swiss clinical trial.
A sample of 196 patients presenting with CRF will be recruited by oncologists from the departments of clinical
oncology at each local study site. All participants will be randomly allocated to the intervention or control group in
a 1:1 ratio. The control group is an active control intervention (CoordiFit) in order to control for potential non-
intended effects such as therapist-patient interaction and participation in a program. Both ERYT and CoordiFit
exercises are easy to learn, and the training sessions will follow the same frequency and duration schedule, i.e., 13
standardized therapy sessions of 45 min (once a week for 6 weeks and then once every second week) during the
total intervention period of 20 weeks. The primary endpoint of the study is the change from baseline over the
whole intervention period (i.e., including measurements at baseline, weeks 8, 14, and 20) in the Functional
Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) subscale score.
Discussion: This study is the first-known randomized clinical trial assessing eurythmy therapy in the treatment of
fatigue in metastatic breast cancer patients. Given the distress that fatigue causes patients, it is important to
validate treatment options. If eurythmy therapy proves beneficial in CRF as part of this randomized controlled
clinical trial, the study may be very impactful with implications not only for metastatic breast cancer patients but
also for other cancer patients, health care personnel, scientists, and funding and regulatory bodies.
(Continued on next page)
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Trial registration: The ERYT/CoordiFit trial was registered at the US National Institutes of Health (ClinicalTrials.gov)
on July 18, 2019, #NCT04024267, and in the portal for human research in Switzerland on December 3, 2019,
#SNCTP000003525.
Keywords: Cancer-related fatigue, Eurythmy therapy, Mindful therapies, Complementary therapies, Metastatic breast
cancer, Randomized controlled trial
Introduction
Cancer-related fatigue (CRF) is the most taxing symp-
tom for many breast cancer patients [1]. Depending on
the methods used for measuring fatigue, patient group
characteristics 15 to 99% of breast cancer patients ex-
perience fatigue during therapy. Also, 25 to 30% of pa-
tients continue to experience fatigue up to 5 years after
completion of treatment or possibly even longer [2]. In
patients with metastatic disease, the prevalence of CRF
exceeds 75% [3, 4]. CRF has been shown to be the symp-
tom that has the largest impact on quality of life [5],
with negative effects on work, social activities, and daily
activities [6–9]. Furthermore, CRF might lead to treat-
ment discontinuation [2].
The pathophysiological mechanism behind CRF has
not been clarified yet and is considered to be multifac-
torial [2, 10].
Currently, there is no gold standard for the treatment
of CRF [2, 11]. The National Comprehensive Cancer
Network (NCCN) Guidelines [3, 12], as well as the
American Society of Clinical Oncology [13], recommend
a combination of approaches. These guidelines and a re-
cent meta-analysis [14] highlight psychosocial interven-
tions (i.e., including education and counseling of patient
and family) and physical activity as having the strongest
evidence base for treating fatigue during and after cancer
treatment. However, physical activity may in itself be too
burdensome for metastatic breast cancer patients due to
metastases or other comorbid illnesses [3]. Pharmaco-
logical treatment, including therapy with antidepressants
or hematopoietic growth factors, is not recommended
[2, 15]. There is increasing evidence that psychostimu-
lants, in particular methylphenidate, are likely to benefit
patients with CRF [15], but the use of pharmacological
agents remains controversial [2, 3]. Finally, there is some
evidence that non-pharmacological mind-body tech-
niques (e.g., tai chi) may be effective in reducing CRF [2,
3, 11, 16–26]. So far, the available data are not suffi-
ciently reliable to formulate final recommendations [27].
Further studies are needed to confirm the effectiveness
of such interventions. Given the prevalence of CRF and
the distress it causes to patients, work to advance new
options to improve fatigue is highly desirable.
Eurythmy therapy has been used for more than 80
years. Eurythmy essentially consists of converting the
sounds of language into movements that regulate and
harmonize healing processes and thus foster recovery and
regaining strength. A key aspect of the eurythmy therapy
is its role in training awareness and self-perception [28–
32], thus inducing physiological and therapeutic effects.
Eurythmy therapy exercises are specific for a distinct med-
ical indication, symptom, or disease [32]. In particular, for
breast cancer patients, the so-called cancer series “O-E-
M-L-I-B-D” is applied [26, 32].
In cancer patients, the demand for mind-body therapies
has increased during recent years [11, 33–38], and breast
cancer patients are more likely to use any complementary
health approach than patients with other cancers [35, 39].
Eurythmy therapy has specific effects in healthy subjects,
such as reducing fatigue [33] and stress [40, 41]. More-
over, studies describe a reduction of a range of symptoms
[42–48], as well as improvements in quality of life [40, 48]
in patients with various chronic diseases and in different
target groups (i.e., children, adolescents, adults) [49, 50].
As observed with other mind-body therapies [51–55], im-
provements have also been described in heart rate vari-
ability (HRV) parameters (i.e., parameters that measure
the adaptability of the autonomic nervous system), as well
as in circadian patterns of HRV, after eurythmy therapy
training [33, 56–59]. This improvement in HRV parame-
ters relates to a change in autonomic regulation toward a
more relaxed pattern and an improvement of complexity
(i.e., adaptability) in the heart rate dynamics. These results
suggest that eurythmy therapy might have positive effects
on the autonomic nervous system. The improved relax-
ation may lead to better stress-coping strategies, a better
circadian rhythm, and ultimately to improved quality of
life. Studies generally report good compliance and satisfac-
tion of participants and patients with eurythmy therapy
[40, 50]. Finally, eurythmy therapy has been used in adults
and children for several decades without any harmful ef-
fects [33, 49, 50].
The aim of this study is to assess the effect of
eurythmy therapy on fatigue in metastatic breast cancer
patients as compared to slow movement fitness.
Methods/design
Study design
The ERYT/CoordiFit study is a randomized controlled,
open-label, two-arm, multi-center superiority trial. A
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sample of 196 female patients with metastatic breast
cancer presenting with CRF will be randomly allocated
to the intervention or control group in a 1:1 ratio. The
control group is an active control intervention (Coordi-
Fit) in order to control for unintended effects such as
the therapist-patient interaction and active engagement
(being part of a program). It consists of slow, standardized
exercises that address physical coordination, stability, bal-
ance, and dexterity. These exercises are non-specific with
respect to CRF and do not include mindfulness features.
The study is planned to be conducted in 14 centers across
Switzerland.
Participants and recruitment
The participants will be recruited by oncologists from
the departments of clinical oncology at each local study
site. Our study will be advertised on the homepage of
the Institute for Complementary and Integrative Medi-
cine and flyers will be available at each study site. Sub-
jects are only included if they meet a pre-defined
FACIT-F subscale score. To avoid bothering subjects by
fully informing them about a study for which they prove
ultimately ineligible, a two-step consenting procedure is
implemented:
(1) Each potential participant will first be asked to sign
a short “preliminary consent” form for completion
of the FACIT-F questionnaire. The oncologist or a
study nurse will explain to the patient briefly the
nature of the study and its purpose and inform her
that she might be eligible for the study depending
on her FACIT-F subscale score. The preliminary
consent form signed by the patient and by the
oncologist or the study nurse will be documented in
the patient’s source documentation.
(2) Eligible patients will then be offered to participate
in the study and, if interested, will be fully informed
about the trial using the full patient information
and informed consent form. Written informed
consent will be obtained before the participant is
submitted to any study procedure. The patient has
at least 24 h to consider whether to participate and
can subsequently send back the signed consent
form by post to the study site (a stamped, addressed
envelope will be provided). A study nurse will
contact the patient by phone after 6 working days if
a patient does not send back the consent form.
Information on the schedule of study procedures
and assessments are shown in Table 1.
Inclusion and exclusion criteria for the trial
Patients who meet the following criteria will be deemed
eligible for the trial: (a) female aged 18 years or older, (b)
CRF according to the FACIT-F (FACIT-F subscale
score < 34 [60]), (c) histologically or cytologically con-
firmed metastatic breast cancer, (d) Eastern Cooperative
Oncology Group (ECOG) grade 0 or 1, (e) ability to
physically and cognitively perform an active movement
therapy, (f) ability to provide informed consent as docu-
mented by signature, and (g) ability to read, write, and
speak German, French, or Italian.
Patients who meet the following criteria will be ex-
cluded from the trial: (a) inability or contraindication
that would prevent prolonged follow-up, or to undergo
the investigated intervention or control intervention, in
the opinion of the investigator; (b) patients with psychi-
atric, addictive or any disorder that prevents the patient
from adhering to the protocol requirements, in the opin-
ion of the investigator; (c) significant uncontrolled car-
diac disease (e.g., unstable angina, recent myocardial
infarction); and (d) hemoglobin < 9 g/dl.
During the trial, all participants will continue to re-
ceive the usual care provided by their health care pro-
viders. Cancer-specific medications/treatments (e.g.,
chemotherapy or radiation therapy, surgery, immuno-
therapy, endocrine therapy) received before or during
the study are documented and examined later in data
analyses, but not restricted.
Randomization
Randomization procedures were implemented at the
Clinical Trial Unit of the University of Bern (CTU Bern)
according to dedicated standard operating procedures.
Allocation will be done by a study nurse via a dedicated
website within the clinical trial management system
REDCap, which also contains the electronic case report
forms. All participants will be randomly allocated to the
intervention or control group in a 1:1 ratio. Randomization
will be stratified by center using permuted blocks with ran-
dom block sizes. Only system administrators who are
otherwise not involved in the trial will have access to the
algorithm and stored lists during the recruitment period.
The underlying randomization lists and details of the algo-
rithm will not be disclosed but kept securely at CTU Bern.
All these measures will help ensure concealment of
allocation.
Endpoints
The primary endpoint of the study is the change from
baseline over the whole intervention period (i.e., includ-
ing measurements at baseline, weeks 8, 14, and 20) in
the Functional Assessment of Chronic Illness Therapy –
Fatigue (FACIT-F) subscale.
Secondary endpoints are the following:
 The change from baseline to the end of intervention
(i.e., including measurements at baseline and at
week 20) in the FACIT-F subscale
Meier-Girard et al. Trials          (2020) 21:612 Page 3 of 12
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 The change from baseline over the whole
intervention period (i.e., including measurements at
baseline, weeks 8, 14, and 20) in the FACT-G, Pitts-
burgh Sleep Quality Index (PSQI), Brief Pain Inven-
tory (BPI), Patient Health Questionnaire-9 (PHQ-9),
General Anxiety Disorder-7 (GAD-7), NCCN Dis-
tress Thermometer, and arm mobility scores.
 Number of patients who return to work during the
intervention phase or the follow-up.
 Retention will be measured by the number, period
to, and reasons for attrition for each group.
Compliance will be measured by the number of
sessions attended, and the number of hours of home
training per week.
 Targeted quantitative metabolomics will be
investigated in 30 patients as a translational research
element. Analysis of amino acids, organic acid
profiles, and acylcarnitine profiles in serum and
urine will be measured with high-performance liquid
chromatography and liquid chromatography-mass
spectrometry, allowing for analysis of over 100 me-
tabolites. Metabolomic data will be measured at
baseline and at the end of intervention (week 20).
Exploratory endpoints of the study are follow-up mea-
surements (6- and 12-month follow-up from week 20) in
FACIT-F subscale, FACT-G, NCCN Distress Thermom-
eter, PSQI, BPI, PHQ-9, GAD-7, and arm mobility.
Outcome measures
Fatigue and quality of life are measured using the FACIT-
F. The FACIT-F belongs to the FACIT family of question-
naires developed by the original Functional Assessment of
Cancer Therapy – General (FACT-G) [61, 62]. FACT-G is
a patient-reported outcome measure used to assess
health-related quality of life in patients undergoing cancer
therapy. It assesses the impacts of cancer therapy in four
primary quality of life domains: physical, social/family,
emotional, and functional well-being. The FACT measure-
ment system is a widely used measure of patient-reported
outcomes in cancer research [63]. FACIT-F consists of the
FACT-G plus the FACIT-F subscale comprising 13
fatigue-related items, with a total of 41 items [64]. The
FACIT-F subscale assesses self-reported fatigue and its
impact on daily activities and function. It has demon-
strated reliability, validity, and responsiveness to change.
The questionnaire is easy to read and quick to complete
(about 10min).
Sleep quality is measured using the PSQI. The PSQI is
a self-rated questionnaire which assesses sleep quality
and disturbances in the past 4 weeks [65]. It is currently
the only standardized clinical instrument that covers a
broad range of indicators relevant to sleep quality [66].
The questionnaire has shown strong reliability and
moderate structural validity [66]. PSQI consists of 19
items divided into 7 component scores: subjective sleep
quality, sleep latency, sleep duration, habitual sleep effi-
ciency, sleep disturbances, use of sleeping medication,
and daytime dysfunction. The sum of scores for these
seven components yields one global score ranging from
0 to 21 [65]. A global score ≤ 5 is associated with good
sleep quality, while a score > 5 is associated with poor
sleep quality. The questionnaire is easy to complete
within 5 to 10min.
Anxiety and depression will be measured using the
GAD-7 (7 items) and the PHQ-9 (9 items), respectively.
Both instruments have evidence of reliability and validity
[67–69].
Pain is measured using the BPI. The BPI is a 9-item
self-report measure that assesses worst, least, and aver-
age levels of pain and the degree to which pain interferes
in activities, mood, relationships, sleep, and enjoyment
of life [70]. This measure is widely used with cancer pa-
tients and has evidence of reliability and validity [70, 71].
Patient distress is measured using the NCCN Distress
Thermometer. The NCCN Distress Thermometer mea-
sures distress on a scale of zero to 10, 10 being the worst
[72]. The NCCN Problem List allows patients to inform
their doctor if they are having concerns in areas such as
practical, family, emotional, spiritual, and physical prob-
lems. This list will not be used as part of this study in
order to limit the number of questions.
The functional status of the patient is measured using
the Patient-Reported Functional Status (PRFS). The
PRFS is a patient-completed measure of performance
status. It is the activities/function domain of the Patient-
Generated Subjective Global Assessment (PG-SGA),
which is a widely-used, well-validated measure used in
patients with cancer [73, 74].
Factors including a patient’s socio-demographic data,
time since diagnosis, stage of disease, initial metastatic
breast cancer or later development, previous and current
cancer therapy, co-morbidities which may cause CRF,
and level of physical activity (at least once a week) are
collected through tailored electronic questionnaires
(medical history and treatments questionnaires and pa-
tient questionnaires) and will be taken into account for
the evaluation of the effect of intervention on CRF.
Study interventions
Both ERYT and CoordiFit exercises are easy to learn,
and the training sessions will follow the same frequency
and duration schedule, i.e., 13 standardized therapy ses-
sions of 45 min (once a week for 6 weeks and then once
every second week) during the total intervention period
of 20 weeks. Patients are instructed by a eurythmy ther-
apist or physical therapist, according to the group of
allocation, in sessions with 1 to 4 patients. Therapists
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are available in all areas of Switzerland, either affiliated
with institutions (e.g., hospitals) or work in private prac-
tices. Patients are asked to additionally train at home 15
min per day, 6 times a week, and compliance of the
home training is reported by the patient in a diary.
All eurythmy and physical therapists will participate in
an introductory teaching session before the start of the
study, to familiarize themselves with the study specifics.
Experimental group: ERYT
The well-established cancer series “O-E-M-L-I-B-D” that
is specific and standardized for breast cancer patients
and which has been applied in breast cancer patients for
decades will also be applied here [26, 32]. Through this
indication-specific concept, the eurythmy therapy distin-
guishes itself from other mindful methods (e.g., tai chi).
In Switzerland, eurythmy therapy is usually prescribed
by physicians. Patients are treated by certified eurythmy
therapists who have successfully completed a standard-
ized 6 years of training, have passed a federal examin-
ation, and hold a federal diploma. For patients,
eurythmy therapy is easy to learn and can be practiced
anywhere (e.g., at home, at work, while traveling) and
irrespectively of an individual medical condition or state
of well-being. Eurythmy therapy also empowers patients
by providing a tool that supports them in being active
and self-reliant. The practices will be introduced using a
standard progression from simpler to more challenging
movements over the course of the intervention depend-
ing on the patients’ capabilities. Patients can perform
and maintain the postures without stress and tension.
Active control intervention: CoordiFit
The CoordiFit program consists of slow, standardized ex-
ercises that address physical coordination, stability, bal-
ance, and dexterity. These exercises serve as a control
intervention and are non-specific with respect to CRF and
breast cancer. They mimic the exercises of ERYT but have
no mindfulness features. The exercises in the control
group focus on movements such as mobilization of the
backbone (roll down with the head toward the feet, verte-
bra by vertebra, coming back up, lastly with the head), the
shoulders (roll shoulders, swing arms), legs (tap with one
foot in front, sideward, and backwards, walking with tap-
ping: coordinate the rhythm with the tap in a walking
movement), balancing (standing and rocking on toes, po-
sitioning the arms, torso, and one leg parallel to the floor),
and coordination exercises (clapping and tapping with
hands and feet, respectively in different orders).
Procedures
Screening (14–1 day(s) prior to allocation)
After providing the signed preliminary informed consent
for completion of the FACIT-F questionnaire, the
patient will be asked to fill in a printed version of the
FACIT-F questionnaire in order to determine whether
she is eligible for the study. The study nurse will enter
the patient’s answers into the dedicated study database
(REDCap). If the FACIT score is < 34, the patient will be
offered a place on the study.
Allocation and baseline (14–0 day(s) prior to first training
session)
After obtaining the patient’s signed informed consent,
the patient will be randomized and the study nurse will
fill in the Medical History and Treatments questionnaire
in REDCap. The study nurse will contact the patient to
specify which group she has been allocated to and will
answer any questions the patient may have. Then, the
study nurse will contact the therapist according to the
group and area of the patient and ask her to call the pa-
tient to arrange the first training session. The patient
will receive via email a link (generated by REDCap) to
open in a web browser the questionnaires to be filled in
(i.e., Patient’s Baseline questionnaire, PSQI, PHQ-9,
GAD-7, BPI, NCCN Distress Thermometer, arm mobil-
ity, and PRFS). These questionnaires constitute the base-
line assessment and consequently must be filled in
before the first session.
Session 1 (week 1)–session 13 (week 20): intervention,
assessment tools/questionnaires, and patient diary
During the intervention phase, the patient will perform
13 sessions of ERYT or CoordiFit. During the whole
intervention phase, regular physical activity (at least once
a week) and compliance with home training will be re-
ported by the patient in a pre-printed diary which will
be provided to the patient. The patient will send back
the diary by postal mail after the last session (addressed
and stamped envelope will be provided by the study
site). At each session, the eurythmy or physical therapist
will record in REDCap whether the patient attended, the
reason if not, and if the patient was able to execute all
movements (therapist’s questionnaire).
Sessions 7 and 10 (weeks 8 and 14): assessment tools/
questionnaires
At weeks 8 and 14, the patient will receive via email a
link (generated by REDCap) to open in a web browser
the questionnaires to be filled in (FACIT-F, PSQI, PHQ-
9, GAD-7, BPI, NCCN Distress Thermometer, and arm
mobility).
Session 13 (week 20): assessment tools/questionnaires and
recording of cancer-specific medications and treatments of
patients
At the last session (at week 20), the patient will receive
via email a link (generated by REDCap) to open in a web
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browser the questionnaires to be filled in (Patient’s Last
Session questionnaire, FACIT-F, PSQI, PHQ-9, GAD-7,
BPI, NCCN Distress Thermometer, arm mobility, and
PRFS). The study nurse will retrospectively verify after
the patient’s last session (at week 20) whether there were
any changes in the therapy during the intervention
period (Medical History and Treatments questionnaire).
The same procedure will be followed in case of
withdrawal.
Six- and 12-month follow-up assessments (from week 20)
Finally, the patient will receive via email a link (gener-
ated by REDCap) to open in a web browser the ques-
tionnaires to be filled in at 6-month and 12-month
follow-up (Patient’s Follow-up questionnaire, FACIT-F,
PHQ-9, GAD-7, BPI, NCCN Distress Thermometer, arm
mobility, and PRFS). After the 12-month follow-up as-
sessment, the study nurse will fill in the questionnaire
“End of Study”. The same procedure will be followed in
case of withdrawal.
Reminders
If a patient has not filled in the questionnaires after 2
days, she will automatically receive a reminder via email
each day for a period of 5 days. The therapist will also
remind the patient to fill in the questionnaires if neces-
sary (status “Incomplete/Partial/Completed Survey Re-
sponse” visible in REDCap).
Withdrawal and discontinuation
Patients can withdraw anytime from the study should
they wish to do so. They will be invited to specify the
reason for withdrawal and to fill in the questionnaire
“end of study”. All data gathered until withdrawal will be
included in the analysis, as laid out in the informed con-
sent document.
The oncologist, as well as the eurythmy therapist or
physical therapist, can decide at any time to exclude the
patient from the study, e.g. in case of concern due to dis-
ease progression. If possible, patients will be asked to fill
in the end of study questionnaire at the time of
withdrawal.
Reporting of adverse events
Evidence suggests that SAEs are not anticipated [40, 49,
75, 76]. Potential minor AEs that may be anticipated are
dizziness, headache, and tension pain in the back and/or
arms [75].
All SAEs will be documented and reported immedi-
ately (within a maximum of 24 h) to the sponsor. Both
the investigator and the sponsor make a causality assess-
ment of the event to the trial intervention. Any event
assessed as possibly, probably, or definitely related is
classified as related to the trial intervention. Both
investigator and sponsor make a severity assessment of
the event as mild, moderate, or severe. Mild means the
complication is tolerable, moderate means it interferes
with daily activities, and severe means it renders daily
activities impossible. If it cannot be excluded that the
SAE occurring is attributable to the intervention under
investigation, the investigator will report it to the Ethics
Committee within 15 days. The SAEs that are a clear re-
sult of the underlying disease (e.g., events occurring due
to breast cancer or metastasis) are events that will not
be reported. AEs and SAEs that are ongoing at study
end are followed up until resolution or stabilization.
An annual safety report is submitted once a year to
the Ethics Committee by the sponsor.
Quality control and data protection
Quality measures
For quality assurance, the sponsor, the Ethics Committee,
or an independent trial monitor may visit the research
sites. Direct access to the source data and all study-related
files is granted on such occasions. All involved parties
keep the participant data strictly confidential.
Data handling and record keeping/archiving/data
management system (hardware and software)
The CRFs in this trial are implemented electronically
using a dedicated electronic data capturing (EDC) sys-
tem (REDCap, https://www.project-redcap.org/). The
EDC system is activated for the trial only after success-
fully passing a formal test procedure. All data entered in
the CRFs are stored on a Linux server in a dedicated
mySQL database. Responsibility for hosting the EDC sys-
tem and the database lies with CTU Bern.
Questionnaires for patients will be prepared in elec-
tronic format and will be accessible through a personal
link. The personal link will be sent to the patient’s email
address. Patients’ email address will be therefore col-
lected into REDCap but this field will be tagged as
“Identifier field” and thus will be automatically removed
from data exports. Patient’s diaries will be prepared in
paper format and handed out by the study nurse at the
site. The patient’s diary will be handed out with a pre-
pared envelope (addressed and stamped) for sending it
back to the sponsor. Date entry from paper diaries into
REDCap will be done by the sponsor. The diaries will
not contain any patient-identifying information.
Electronic and central data validation
Data is checked by the EDC system for completeness
and plausibility. Furthermore, selected data points are
cross-checked for plausibility with previously entered
data for that participant. In addition, central data reviews
will be performed by the sponsor on a regular basis to
ensure completeness of the data collected and the
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accuracy of the primary outcome data. Before the data-
base locks, the principal investigator in each center will
validate the collected data with his signature.
Source documents
Source documents must be available at the site to docu-
ment the existence of the study participant and must in-
clude the original documents relating to the study, as
well as the medical treatment and medical history of the
participant.
Source documents are considered (list not conclusive):
– Preliminary consent form and informed consent form
– Electronic/paper version of completed patient
questionnaires (Medical history and treatments
questionnaires, Patient’s Baseline questionnaire,
Therapist’s questionnaire, Patient’s Last Session
questionnaire, Patient’s Follow-up questionnaire,
End of Study questionnaire, FACIT-F, PSQI, PHQ-9,
GAD-7, BPI, NCCN Distress Thermometer, mobility
of the arm, PRFS)
– Patient’s diary
Confidentiality and coding
Trial and participant data will be handled with uttermost
discretion and is only accessible to authorized personnel
who require the data to fulfill their duties within the
scope of the study. On the CRFs and other study-
specific documents, participants are only identified by a
unique participant number. The names of the patients
will not be disclosed. The participant number list will be
stored at the Institute of Complementary and Integrative
Medicine.
The server hosting the EDC system and the database
is kept in a locked server room. Only the system admin-
istrators have direct access to the server and back-up
tapes. A role concept with personal passwords (site in-
vestigator, statistician, monitor, administrator, etc.) regu-
lates permission for each user to use the system and
database as he/she requires.
All data entered into the CRFs are transferred to the
database using Transport Layer Security (TLS) encryp-
tion. Each data point has attributes attached to it identi-
fying the user who entered it with the exact time and
date. Retrospective alterations of data in the database are
recorded in an audit table. Time, table, data field and al-
tered value, and the person are recorded (audit trail).
A multi-level back-up system is implemented. Back-
ups of the whole system including the database are run
internally several times per day and on external tapes
once a day. The back-up tapes are stored in a secure
place in a different building.
Retention and destruction of study data
At final analyses, data files will be extracted from the
database into statistical packages to be analyzed. After
database lock, the status of the database is recorded in
special archive tables. The sponsor will keep the Trial
Master File, the extracted data, the metadata, and in-
terim/final reports for at least 10 years.
Monitoring
Monitoring is performed by employee(s) of the sponsor
who have received an introductory training on basic
monitoring principles by CTU Bern. There is no Trial
Steering Committee and no Stakeholder and Public In-
volvement Group (SPIG).
Site initiation visit
Site initiation visits are performed by the sponsor ac-
cording to the Standard Operating Procedures (SOP)
from CTU Bern.
Central data monitoring
Central data monitoring will be performed by the spon-
sor in order to ensure the overall completeness of data
entry as well as plausibility and consistency of selected
data points.
On-site monitoring visit(s)
No regular on-site monitoring visits will be performed
for this study. Instead, monitoring visits are planned fol-
lowing a risk-based approach, with monitoring visits
scheduled according to defined key performance indica-
tors which will be checked at regular time points (ca.
quarterly). However, sites may also be selected for a
monitoring visit at random or whenever it is deemed ne-
cessary/appropriate by the sponsor at any time during
trial conduct.
Any findings and comments during the monitoring
visits will be documented in site visit reports and com-
municated to the local investigator and the sponsor. All
source data and relevant documents will be accessible to
monitors and questions to monitors are answered during
site visits.
Protocol amendments
The sponsor manages submission to the local Ethics
Committees. Site personnel should be trained in the
course of the study on any protocol amendment and any
re-training should be provided as necessary. Self-training
by site personnel may be acceptable, e.g., for non-
substantial amendments. The local principal investigator
is responsible that his/her site personnel is properly
trained.
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Sample size calculation and statistical analysis
Sample size
Eurythmy therapy is expected to have a greater effect on
CRF than the control intervention. A validated Minimal
Clinically Important Difference (MCID) for FACIT-F
subscale is defined as a change in score of 3–4 points
[62]. We assume a non-parallel course over time of the
FACIT-F subscale score between the ERYT group and
the control group and a difference ≥ 4 in the FACIT-F
subscale score between the two groups at the end of the
intervention (week 20).
The mean FACIT-F subscale score at baseline for the
two groups was assumed to be 30 points with a standard
deviation of 10 points [60]. Simulations confirmed that
the sample size of N = 156 patients (excluding drop-
outs) will provide enough power (≥ 80%) to reject the
null-hypothesis of no interaction between the group and
time at the α = 0.05 level, if the effect of the ERYT inter-
vention on the FACIT-F subscale score at the end of
therapy is 4 points, if the standard deviation of the
FACIT-F subscale score is ≤ 12 points, and if the within-
patient variation between two measurements is ≤ 8
points. The simulations also confirmed that the power
of 80% is reached in case of slight deviations from the
assumptions if the difference between groups ≥ 4 points
at the end of the intervention. To account for a dropout
rate of 20%, the total sample size will be N = 196 patients
(98 per group).
In order to ensure the study population can comply
with the intervention as excepted, we will check feasibil-
ity issues, i.e., the number of sessions completed and
compliance with home training, after the inclusion of 50
patients.
Statistical analysis
A nonparametric ANOVA model for longitudinal data,
the F1-LD-F1 model of Brunner, Domhof, and Langer,
will be applied to model the course of the FACIT-F sub-
scale scores from baseline over the whole intervention
[77]. The first F1 means that there is one group factor,
the second that there is one-time or repeated measures
factor. The main hypotheses are the following:
H0: there is no interaction of the treatment arm with
the time;
H1: there is an interaction of the treatment arm with
the time (favoring ERYT).
Least-square means of the original data (original
scales) and 95% confidence intervals will be calculated
and displayed in figures over time.
Differences from baseline to end of intervention will
be analyzed by stratified Wilcoxon rank-sum tests (via
ordinal logistic regression, i.e., proportional odds model
with baseline measurements as co-variable, treatment
arm as binary predictor and differences as outcome
variable). Least-squares means of the original differences
and 95% confidence intervals will be calculated.
Exploratory endpoints will be analyzed descriptively
using mean and standard deviation or median and inter-
quartile, as appropriate.
Statistical analysis will be conducted applying an
intention-to-treat approach, and therefore including all
randomized patients. In case of protocol non-adherence,
a per-protocol analysis will be conducted to estimate the
robustness of the primary estimates. All tests will be
two-sided with a significance level of 0.05. Statistical
analysis will be performed using R [78].
Dissemination
Findings from the study will be published in peer-
reviewed scientific journals, preferably in those with an
open-access approach. Furthermore, results will be pre-
sented at international conferences on the subject of
matter.
Discussion
To our knowledge, this study is the first randomized
clinical trial assessing eurythmy therapy as treatment for
fatigue in metastatic breast cancer patients. Currently,
there is no gold standard for the treatment of cancer-
related fatigue. Physical activity can reduce CRF and is
recommended during and after cancer treatment. How-
ever, it may be too burdensome for patients with meta-
static breast cancer.
The first challenge we faced in designing this study
was the choice of the control group. In order to control
for unintended effects such as the therapist-patient
interaction and active engagement (participation in a
program), an active control intervention has been set up.
The exercise specialist from our team developed the
CoordiFit program, including similar movements as in
ERYT but without mindfulness features. A second chal-
lenge was the data collection procedures. As patients
have no hospital visits scheduled as part of the study
during the intervention and follow-up periods, all ques-
tionnaires are sent via email to the patients. The clinical
trial management system REDCap allows emails, includ-
ing reminders, to be sent automatically to the patients.
The physical and eurythmy therapists will also remind
the patient to fill in the questionnaires.
Given that the success of eurythmy therapy depends
on the regularity of the home training/compliance with
the home training, participants are asked to record their
exercises in a pre-printed patient diary during the whole
intervention period. Studies generally report good com-
pliance and satisfaction of participants with eurythmy
therapy [40, 50].
Fatigue and major confounding factors/effect modifiers
are assessed using validated questionnaires (e.g., FACIT-
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F for fatigue and quality of life, PSQI for sleeping distur-
bances, BPI for pain, GAD-7 for anxiety, PHQ-9 for de-
pression, and NCCN Distress Thermometer for patient’s
distress). In order to limit the number of questionnaires,
social support is assessed by the subscale social/family
well-being from FACIT-F. Since the intervention might
also have a beneficial effect on the major confounding
factors, these confounding factors are evaluated as
secondary endpoint variables as well. All potential
confounding factors including the patient’s socio-
demographic data, time since diagnosis, stage of disease,
initial metastatic breast cancer or later development,
previous and current cancer therapy, co-morbidities
which may cause CRF, and level of physical activity (at
least once a week) will be taken into account for the
evaluation of the effect of intervention on CRF.
Finally, advanced cancer populations are under-
represented in clinical trials with non-pharmacological
interventions. Given the distress that CRF causes pa-
tients, it is important to validate treatment options. This
trial is a low-risk study and constitutes a novel approach
to treat CRF. The expected results of the proposed re-
search will be significant for several stakeholders.
 For patients, if eurythmy therapy is proven to be an
effective therapeutic option, it will improve their
fatigue, quality of life, and everyday life.
 For clinicians, if eurythmy therapy is proven to be
beneficial, it will contribute to optimizing therapy
for patients with CRF. Additionally, since CRF also
constitutes a dose-limiting side effect for chemother-
apy, improving CRF with eurythmy therapy may en-
able higher dosages or longer continuation of
chemotherapy, which in turn may lead to a higher
effectiveness and improve the outcome of
chemotherapy.
 From a scientific point of view, given that no
satisfactory therapy yet exists for CRF, further
research to advance therapy including novel
treatment approaches is highly desirable. This trial
could pave the way for a safe and beneficial
treatment option as well as future studies.
 Funding bodies could distinguish themselves by
supporting scientific investigations of novel
approaches in the treatment of CRF.
Trial status
The overall study duration is 4 years, which includes a
planned recruitment period of 36 months. The study
duration for each patient is 20 weeks plus 2 follow-up
visits at 6 and 12 months after the end of the interven-
tion. The estimated study start date is March 2020. Esti-
mated completion of recruitment is March 2022.
The protocol has been approved by the Ethics Com-
mittee of the Canton Bern. Due to the legal regulation in
Switzerland, the usual procedure is to, firstly, submit
and obtain approval of the Ethics Committee of a dis-
tinct Swiss Canton as a single center trial (University
Hospital Bern). If that approval is obtained, participation
of other centers and centers in other cantons will be
later registered prior to their participation in the trial.
Therefore, after we obtained the approval from the Eth-
ics Committee, we translated all documents for the pa-
tients into French and Italian such that centers from all
language regions Switzerland can participate. After-
wards, we have submitted an amendment that modifies
the study as a multi-center trial, including the new docu-
ments in French and Italian. The amendment is cur-
rently under review by the respective Ethics Committee
offices.
Protocol version number and date: version 2-1 (dated
December 16, 2019).
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